New York Entertainment Guide
SEE OTHER BRANDS

Top arts and entertainment news from New York

New York Entertainment Guide: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New York Entertainment Guide.

Press releases published on May 18, 2025

SIENNA and WCEA Forge Global Partnership to Advance Nursing Education and Equity

SIENNA and WCEA Forge Global Partnership to Advance Nursing Education and Equity

A Strategic Partnership Empowering Nurses Worldwide with Accessible, High-Quality Continuing Education and Professional Development Opportunities NEW YORK, NY, UNITED STATES, May 18, 2025 /⁨EINPresswire.com⁩/ -- — The Society of Internationally Educated …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA).  Such investors are advised to contact Danielle Peyton at newaction@ …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Coinbase Global, Inc.- COIN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Coinbase Global, Inc.- COIN

NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Coinbase Global, Inc. (“Coinbase” or the “Company”) (NASDAQ: COIN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  …

Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

 Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT-FOM …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service